Literature DB >> 21040411

Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice.

Ludwig Amigo1, Constanze Husche, Silvana Zanlungo, Dieter Lütjohann, Marco Arrese, Juan Francisco Miquel, Attilio Rigotti, Flavio Nervi.   

Abstract

BACKGROUND & AIMS: Bile acid (BA) pool size remains unchanged after cholecystectomy (XGB) but it circulates faster, exposing the enterohepatic system to an increased flux of BA. Triglyceride (TG) and BA metabolisms are functionally inter-related. We investigated whether ablation of the gallbladder (GB) modifies hepatic TG metabolism.
METHODS: Male mice were subjected to XGB and fed a normal diet. In some experiments, mice received a 1% nicotinic acid diet to block lipolysis. Parameters of BA and TG metabolism, and microsomal triglyceride transfer protein (MTTP) activity were measured 1-2 months after XGB. Serum parameters, hepatic lipids and mRNA expression of genes of lipid metabolism were determined.
RESULTS: BA pool size and synthesis were normal, but biliary BA secretion doubled during the diurnal light phase in XGB mice. Serum and hepatic TG concentrations increased 25% (P<0.02), and hepatic very-low-density lipoproteins (VLDL)-TG and apoB-48 productions increased 15% (P<0.03) and 50% (P<0.01), respectively, after XGB. Feeding a 1% nicotinic acid did normalize VLDL production. MTTP activity increased 15% (P<0.005) after XGB. Hepatic free fatty acid (FFA) synthesis and content, and mRNA levels of lipid metabolism-related genes remained normal in XGD mice.
CONCLUSIONS: XGB increased serum and hepatic TG levels, and VLDL production, which were restored to normal by nicotinic acid. The results suggest that FFA flux from adipose tissue to the liver is increased in XGB mice. They support the hypothesis that the GB has a role in the regulation of hepatic TG metabolism and that XGB may favour the accumulation of fat in the liver.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21040411     DOI: 10.1111/j.1478-3231.2010.02361.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  23 in total

Review 1.  Cholecystectomy and risk of metabolic syndrome.

Authors:  Agostino Di Ciaula; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Eur J Intern Med       Date:  2018-04-26       Impact factor: 4.487

2.  Cholecystectomy does not significantly increase the risk of fatty liver disease.

Authors:  Hong-Gang Wang; Li-Zhen Wang; Hang-Jiang Fu; Peng Shen; Xiao-Dan Huang; Fa-Ming Zhang; Rui Xie; Xiao-Zhong Yang; Guo-Zhong Ji
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

3.  Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population.

Authors:  Min-Sun Kwak; Donghee Kim; Goh Eun Chung; Won Kim; Yoon Jun Kim; Jung-Hwan Yoon
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

4.  Screen-detected gallstone disease and cardiovascular disease.

Authors:  Daniel Mønsted Shabanzadeh; Tea Skaaby; Lars Tue Sørensen; Torben Jørgensen
Journal:  Eur J Epidemiol       Date:  2017-05-27       Impact factor: 8.082

5.  Absorption mechanism of DHP107, an oral paclitaxel formulation that forms a hydrated lipidic sponge phase.

Authors:  Yura Jang; Hye Jin Chung; Jung Wan Hong; Cheol-Won Yun; Hesson Chung
Journal:  Acta Pharmacol Sin       Date:  2016-11-21       Impact factor: 6.150

6.  Cholecystectomy Causes Ultrasound Evidence of Increased Hepatic Steatosis.

Authors:  Sangchul Yun; Dongho Choi; Kyeong Geun Lee; Han Joon Kim; Bo-Kyeong Kang; Hyunsung Kim; Seung Sam Paik
Journal:  World J Surg       Date:  2016-06       Impact factor: 3.352

7.  Metabolic effects of cholecystectomy: gallbladder ablation increases basal metabolic rate through G-protein coupled bile acid receptor Gpbar1-dependent mechanisms in mice.

Authors:  Víctor Cortés; Ludwig Amigo; Silvana Zanlungo; José Galgani; Fermín Robledo; Marco Arrese; Francisco Bozinovic; Flavio Nervi
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

8.  Cholecystectomy does not worsen progression or outcomes in non-alcoholic fatty liver disease.

Authors:  Donny Kakati; Ujjwal Kumar; Kirk Russ; Mohamed Shoreibah; Yong-Fang Kuo; Bradford Jackson; Ashwani K Singal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-01-05

9.  Cholelithiasis and the risk of liver cancer: results from cohort studies of 134,546 Chinese men and women.

Authors:  Emily Vogtmann; Xiao-Ou Shu; Hong-Lan Li; Wong-Ho Chow; Gong Yang; Bu-Tian Ji; Hui Cai; Chang Yu; Yu-Tang Gao; Wei Zheng; Yong-Bing Xiang
Journal:  J Epidemiol Community Health       Date:  2014-02-26       Impact factor: 3.710

Review 10.  Cholecystectomy as a risk factor for metabolic dysfunction-associated fatty liver disease: unveiling the metabolic and chronobiologic clues behind the bile acid enterohepatic circulation.

Authors:  Li Qi; Wanlin Dai; Jing Kong; Yu Tian; Yongsheng Chen
Journal:  J Physiol Biochem       Date:  2021-07-24       Impact factor: 4.158

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.